4BIO Capital: Investment Portfolio & Startup News
4BIO Capital
To add a bio or update investment portfolio click update information.
Investment Portfolio


Undecimal Bio
13 Oct 2026
Undecimal Bio lands a £14m seed round led by 4BIO Capital and IQ Capital to unlock targeted delivery of RNA drugs beyond the liver
Undecimal Bio is a platform biotechnology company developing DELiveri, an AI-enabled synthetic biology platform for targeted delivery of siRNA therapeutics. DELiveri identifies conjugates that direct RNA medicines to defined cell types beyond the liver, with an initial focus on renovascular disease.


Cytospire Therapeutics
5 May 2026
Cytospire Therapeutics secures £61m Series A led by 4BIO Capital for cancer therapies that activate the body’s immune cells
Cytospire Therapeutics develops multispecific immune cell engager antibodies designed to enhance and direct the activity of the body’s immune system. Its platform targets gamma delta T cells to generate anti tumour immune responses for patients with cancer and other diseases.
4BIO Capital
- 2(12 months)
- 4biocapital.com
More venture news
- 16 Nov 2026

AlectoAlecto raises a £15m seed round led by Insight Partners to deliver premium legal services for the mass market
SeedLegal - 11 Nov 2026

TendrilsTendrils lands a £23m seed round led by Benchmark to rebuild a computer chip that handles thousands of tasks at once
SeedDeep Tech - 13 Nov 2026

Pro Climbing LeaguePro Climbing League lands a £3m seed round led by Redrice Ventures to bring professional climbing competitions to cities worldwide
SeedConsumer